ergometrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| ergot alkaloid derivatives | 1042 | 60-79-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An ergot alkaloid (ERGOT ALKALOIDS) with uterine and VASCULAR SMOOTH MUSCLE contractile properties.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | mg | O |
| 0.20 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.02 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AB03 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids |
| CHEBI has role | CHEBI:27026 | toxins |
| CHEBI has role | CHEBI:33295 | diagnostic aid |
| CHEBI has role | CHEBI:36063 | oxytocic agents |
| CHEBI has role | CHEBI:76946 | fungal metabolites |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum hemorrhage | indication | 47821001 | |
| Postabortal Hemorrhage | indication | ||
| Incomplete miscarriage | off-label use | 156072005 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Pregnancy-induced hypertension | contraindication | 48194001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Seizure disorder | contraindication | 128613002 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Sepsis syndrome | contraindication | 238150007 | |
| Pregnancy, function | contraindication | 289908002 | |
| Arteriosclerosis obliterans | contraindication | 361133006 | DOID:5160 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.56 | acidic |
| pKa2 | 13.5 | acidic |
| pKa3 | 7.01 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(1A) dopamine receptor | GPCR | Ki | 5.53 | DRUG MATRIX | |||||
| D(2) dopamine receptor | GPCR | EC50 | 8 | WOMBAT-PK | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.20 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 8.33 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | EC50 | 8.50 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 8.58 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.96 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 8.82 | DRUG MATRIX | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.88 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.71 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | EC50 | 9 | WOMBAT-PK | |||||
| Alpha-1B adrenergic receptor | GPCR | Kd | 6.37 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1E | GPCR | EC50 | 7.70 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 8.89 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 8.09 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | AGONIST | Ki | 8.50 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4017426 | VUID |
| N0000179118 | NUI |
| D01163 | KEGG_DRUG |
| 129-51-1 | SECONDARY_CAS_RN |
| 4017426 | VANDF |
| 4022085 | VANDF |
| C0014704 | UMLSCUI |
| CHEBI:4822 | CHEBI |
| CHEMBL119443 | ChEMBL_ID |
| CHEMBL1213135 | ChEMBL_ID |
| DB01253 | DRUGBANK_ID |
| 443884 | PUBCHEM_CID |
| 148 | IUPHAR_LIGAND_ID |
| 24313 | RXNORM |
| 3591 | MMSL |
| 4673 | MMSL |
| d00586 | MMSL |
| 001305 | NDDF |
| 004940 | NDDF |
| 126071000 | SNOMEDCT_US |
| 126072007 | SNOMEDCT_US |
| 54541002 | SNOMEDCT_US |
| D004874 | MESH_DESCRIPTOR_UI |
| 390 | INN_ID |
| YMH3D0ZJWV | UNII |
Pharmaceutical products:
None